{
    "nctId": "NCT01172223",
    "briefTitle": "Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer",
    "officialTitle": "Phase I/II Trial of Primary Chemotherapy With Non-pegylated Liposomal Doxorubicin, Paclitaxel and Lapatinib in Patients With HER2-positive Early",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 81,
    "primaryOutcomeMeasure": "Determine the optimal doses for NPLD, paclitaxel and lapatinib (phase I)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed breast cancer\n* T1c N1-2 or T2 N0-2 disease\n* HER2-positive tumours with 3+ intensity on immunohistochemical staining for HER2 or amplification of the HER2 gene on fluorescence in situ hybridization (FISH)\n* No prior systemic treatment regimens for breast cancer\n* Adequate hematologic function (ANC 1500 cells/\u00b5l, platelet count 100000/\u00b5l, and hemoglobin 8g/dl).\n* Serum creatinine concentration \\< 1.5 times the upper limit of normal (ULN) and/or creatinine clearance \\>60 ml/min\n* Bilirubin level \\< 1.5 X ULN\n* Normal cardiac function with a left ventricular ejection fraction of at least 50% (as assessed by quantitative echocardiogram or MUGA scan)\n* Karnofsky performance status 80%\n* Age 18 years\n* If the patient is of childbearing potential, she agrees to: comply with effective contraceptive measures, has been using adequate contraception since the last menses, will use adequate contraception during the study, and has a negative pregnancy test within one week of study entry\n* Written informed consent prior to admission to this study\n\nExclusion Criteria:\n\n* Male patients\n* Inflammatory or bilateral breast cancer\n* Evidence of distant metastases\n* Previous systemic or local treatment for breast cancer (including surgery, radiotherapy, cytotoxic and endocrine treatments)\n* Past or current history of other neoplasms, except for\n* Curatively treated non-melanoma skin cancer\n* Adequately treated in situ carcinoma of the cervix\n* Other cancer curatively treated and with no evidence of disease for at least 5 years\n* Significant cardiac disease, including angina pectoris, severe cardiac arrhythmia requiring medication, severe conduction abnormalities, clinically significant valvular disease, cardiomegaly, ventricular hypertrophy, poorly uncontrolled hypertension (resting diastolic blood pressure \\>115 mmHg), prior myocardial infarction, CHF, or other cardiomyopathy\n* Preexisting sensoric or motor polyneuropathy Grade 2 according to NCI CTC\n* Serious intercurrent medical or psychiatric illness, including serious active infection\n* Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study entry.\n* Detained persons or prisoners\n* Pregnant or nursing women",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}